AIDS reviews最新文献_第8页

A Systematic Review of Magnetic Resonance Imaging Studies in Perinatally HIV-Infected Individuals. 围产期hiv感染者磁共振成像研究的系统综述

IF 2.2 4区医学

AIDS reviews Pub Date : 2021-12-29 DOI: 10.24875/AIDSRev.20000088

Manuela Martín-Bejarano, Beatriz Ruiz-Saez, Ana Martinez-de-Aragón, Helena Melero, Berta Zamora, Norberto A Malpica, Jose T Ramos, Maria I Gonzalez-Tomé

{"title":"A Systematic Review of Magnetic Resonance Imaging Studies in Perinatally HIV-Infected Individuals.","authors":"Manuela Martín-Bejarano, Beatriz Ruiz-Saez, Ana Martinez-de-Aragón, Helena Melero, Berta Zamora, Norberto A Malpica, Jose T Ramos, Maria I Gonzalez-Tomé","doi":"10.24875/AIDSRev.20000088","DOIUrl":"https://doi.org/10.24875/AIDSRev.20000088","url":null,"abstract":"Over the past few years, neuroimaging studies have been performed in young adults with perinatally acquired HIV (PHIV) to study the impact of HIV infection on the central nervous system (CNS), but no recent review have been published. This review aims to identify brain areas where PHIV eems to have greater impact taking into account demographic, behavioral, and clinical characteristics in PHIV infected patients. For this purpose, PubMed and Medline searches were carried out which included studies from 2010 to April 2020. We performed a systematic review and included 26 articles using structural (brain morphometry and diffusion tensor imaging) and functional magnetic resonance imaging methods involving 1182 PHIV-infected participants. Ample evidence has been provided of HIV effects on underlying brain structure. However, information recorded in the studies is commonly incomplete and results sometimes contradictory. In addition to future improvements and dissemination of tools for the developing brain MRI processing and analysis, the inclusion of data related to HIV infection itself (including clinical and immunovirological characteristics as well as detailed information about antiretroviral treatment such as age at ART initiation) may be of vital importance to the better understanding of the impact of the disease on CNS.","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2021-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25491807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Safety of Antiretroviral Therapy in the Treatment of HIV/AIDS in Children: Systematic Review and Meta-analysis. 抗逆转录病毒治疗儿童HIV/AIDS的安全性:系统评价和荟萃分析。

IF 2.2 4区医学

AIDS reviews Pub Date : 2021-12-29 DOI: 10.24875/AIDSRev.200001071

Renata Szpak, Natália F Lombardi, Frederico A Dias, Helena H L Borba, Roberto Pontarolo, Astrid Wiens

{"title":"Safety of Antiretroviral Therapy in the Treatment of HIV/AIDS in Children: Systematic Review and Meta-analysis.","authors":"Renata Szpak, Natália F Lombardi, Frederico A Dias, Helena H L Borba, Roberto Pontarolo, Astrid Wiens","doi":"10.24875/AIDSRev.200001071","DOIUrl":"https://doi.org/10.24875/AIDSRev.200001071","url":null,"abstract":"The safety of using different antiretroviral therapies (ART) in pediatric HIV/AIDS patients is not well-established. Therefore, this study aimed to assess the safety of ART in children. A systematic review of randomized clinical trials (RCTs) was conducted to assess the safety of ART used by pediatric patients living with HIV/AIDS. The electronic search was conducted in PubMed and Scopus, in addition to a manual search. Studies were included if they assessed the safety of ART compared to placebo or another ART. Direct and indirect meta-analyses were conducted regarding safety outcomes. The systematic review included 21 RCTs. The studies included more than 5500 participants, and age ranged from 3 months to 18 years. The drugs evaluated were nucleoside reverse transcriptase inhibitors (NRTI); non-NRTI; and protease inhibitors. The predominant route of infection was vertical. Direct meta-analyses were performed for the outcomes sleep disorders, hepatobiliary disorders, respiratory disorders, hypertransaminasemia, neutropenia, hospitalization, and death. For these outcomes, no statistically significant differences were found. Indirect meta-analyses were performed for the outcomes anemia, gastrointestinal disorders, liver disorders, severe adverse events (AE), AE that led to changes in treatment, fever, and skin manifestations. However, no statistically significant differences were found for these outcomes. In this study, non-significant differences were detected in the safety of different ART used in pediatric individuals. The choice of appropriate therapy should be based on its efficacy and the individual characteristics of each patient.","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2021-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39057820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The opioid epidemic during the COVID-19 pandemic: Impact on HIV and HCV control. COVID-19大流行期间阿片类药物流行:对艾滋病毒和丙型肝炎病毒控制的影响

IF 2.2 4区医学

AIDS reviews Pub Date : 2021-12-29 DOI: 10.24875/AIDSRev.M21000046

Ana Treviño, Vicente Soriano

引用次数: 0

Another patient has cured HIV infection. 另一名患者治愈了艾滋病毒感染。

IF 2.2 4区医学

AIDS reviews Pub Date : 2021-12-29 DOI: 10.24875/AIDSRev.M21000045

Carmen de Mendoza, Vicente Soriano

引用次数: 0

Nutritional assessment in the HIV-infected older population receiving antiretroviral therapy. 接受抗逆转录病毒治疗的老年艾滋病毒感染者的营养评估。

IF 2.2 4区医学

AIDS reviews Pub Date : 2021-12-22 DOI: 10.24875/AIDSRev.21000051

Tippawan Siritientong, Daylia Thet

引用次数: 0

New insights into the genetics of same-sex behavior. 对同性行为的遗传学有了新的认识。

IF 2.2 4区医学

AIDS reviews Pub Date : 2021-10-04 DOI: 10.24875/AIDSRev.M21000043

Lucia Gallego, Manuel de Santiago, Vicente Soriano

引用次数: 0

Dolutegravir in Mexico for special populations: A cost analysis perspective. Dolutegravir在墨西哥用于特殊人群:成本分析视角。

IF 2.2 4区医学

AIDS reviews Pub Date : 2021-07-01 DOI: 10.24875/AIDSRev.M21000042

Banda Marco, Herrera Cristina, Reynaga Cristhian, Rangel Sigfrido, Josue Del Angel, Angel Reyes, Prudente Isidoro

{"title":"Dolutegravir in Mexico for special populations: A cost analysis perspective.","authors":"Banda Marco, Herrera Cristina, Reynaga Cristhian, Rangel Sigfrido, Josue Del Angel, Angel Reyes, Prudente Isidoro","doi":"10.24875/AIDSRev.M21000042","DOIUrl":"https://doi.org/10.24875/AIDSRev.M21000042","url":null,"abstract":"Integrase strand-transfer inhibitors (INSTI) are the latest class of antiretrovirals registered in Mexico. They include raltegravir (RAL), elvitegravir/cobicistat (EVG/c), dolutegravir (DTG) and bictegravir (BIC). Along with international guidelines, Mexico adopted the use of INSTI about two years ago as initial antiretroviral therapy (ART). This is partially due to the increase in the pre-treatment resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI), mainly efavirenz (EFV). Furthermore, INSTI depict greater efficacy, safety and less drug-drug interactions than NNRTI and protease inhibitors (PI). DTG is a second generation INSTI with a high barrier to resistance. It is recommended in international and national guidelines in a wide variety of clinical scenarios for persons living with human immunodeficiency virus (HIV) (PLWHIV), including treatment-naïve, first-line NNRTI treatment failure, simplification switch in suppressed patients, pregnancy, women with childbearing potential, adolescents and children over 6 years of age. DTG is mostly metabolized by the liver UDP-glucuronosyltransferase, and exhibits low drug-drug interactions overall; on the other hand, it has an extremely low renal elimination, therefore may be used in PLWHIV with advanced kidney disease without dose modification. Tuberculosis is a common coinfection in Mexico that requires rifampin-based anti-tuberculosis therapy, which requires increasing DTG to double dosing (50 mg BID). In Mexico, DTG-based regimens are likely to be cost-effective in many scenarios, given its acquisition costs and the particularities of the HIV population and associated clinical conditions, including a relatively high proportion of the following: i) new HIV diagnoses presenting at acquired immunodeficiency syndrome (AIDS) stage; ii) high rate of tuberculosis coinfection; iii) frequent first-line NNRTI treatment failures; and iv) relatively high proportion of infected children and adolescents.","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39048694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 in Madrid: Leading Pandemic Control after being the Spanish Epicenter. 2019冠状病毒病在马德里:成为西班牙疫情中心后的领先流行病控制。

IF 2.2 4区医学

AIDS reviews Pub Date : 2021-06-07 DOI: 10.24875/AIDSRev.M21000041

Vicente Soriano, José Vicente Fernández-Montero

引用次数: 0

Efficacy and Safety of Triple versus Dolutegravir-based Dual Therapy in Patients with HIV-1 Infection: A Meta-analysis of Randomized Controlled Trials. HIV-1感染患者三联治疗与多曲地韦双重治疗的疗效和安全性:随机对照试验的荟萃分析

IF 2.2 4区医学

AIDS reviews Pub Date : 2021-06-03 DOI: 10.24875/AIDSRev.20000103

Yuanlu Shu, Chengfeng Qiu, Xiaojun Tu, Ziwei Deng, Ye Deng, Hongqiang Wang, Xiang Zhao, Zhihua Shi

{"title":"Efficacy and Safety of Triple versus Dolutegravir-based Dual Therapy in Patients with HIV-1 Infection: A Meta-analysis of Randomized Controlled Trials.","authors":"Yuanlu Shu, Chengfeng Qiu, Xiaojun Tu, Ziwei Deng, Ye Deng, Hongqiang Wang, Xiang Zhao, Zhihua Shi","doi":"10.24875/AIDSRev.20000103","DOIUrl":"https://doi.org/10.24875/AIDSRev.20000103","url":null,"abstract":"A new strategy of simplification therapy shown the unique benefits in clinical treatment, by reducing pill burden and avoid drug exposure. To provide more evidence for the strategy, we compared the efficacy and safety of dolutegravir (DTG)-containing simplified dual combination antiretroviral therapy (cART) and traditional triple cART for people living with HIV/AIDS. The meta-analysis of randomized controlled trials compared DTG-containing dual therapy with triple cART. The primary outcome was virologic suppression. The secondary outcomes included CD4T cell recovery, lipids change from baseline, and adverse events (AEs). A total of 7 studies, 4852 patients were eligible, 2423 (49.9%) received DTG-based simplified dual cART, and 2429 (50.1%) received triple cART. The viral suppression rate was 94.7% at 24 weeks, 93.0% at 48 weeks, and 96.6% at 96 weeks in dual cART. The viral suppression rate of dual cART was non-inferior to triple cART at 24 weeks (risk difference [RD], -0.00; 95% confidence interval [CI] -0.02-0.01), at 48 weeks (RD, -0.01; 95% CI -0.02-0.01), and at 96 weeks (RD, -0.01; 95% CI -0.02-0.00). Sub-analysis results were consistent with the overall results. With regard to other outcomes (CD4T counts, lipids, any AEs, and AEs grade ≥ 3), there was no significant statistical difference between the two regimens. DTG-based simplified dual cART was non-inferior to triple cART in terms of efficacy and safety. This finding provides strong support for current consensus guidelines recommended the dual regimen as first-line treatment.","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2021-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39057817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Differentials of SARS-CoV-2 Viral RNA Re-positivity in Discharged COVID-19 Patients. 出院COVID-19患者SARS-CoV-2病毒RNA再阳性的差异

IF 2.2 4区医学

AIDS reviews Pub Date : 2021-06-03 DOI: 10.24875/AIDSRev.21000023

Jiliang Xia, Ying Zeng, Zhenghong Tan, Ting Chen, Weilan Hu, Shulei Shuai, Deliang Cao, Xi Zeng

{"title":"Differentials of SARS-CoV-2 Viral RNA Re-positivity in Discharged COVID-19 Patients.","authors":"Jiliang Xia, Ying Zeng, Zhenghong Tan, Ting Chen, Weilan Hu, Shulei Shuai, Deliang Cao, Xi Zeng","doi":"10.24875/AIDSRev.21000023","DOIUrl":"https://doi.org/10.24875/AIDSRev.21000023","url":null,"abstract":"The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious RNA coronavirus responsible for the pandemic of the coronavirus disease 2019 (COVID-19). Recent advances in virology, epidemiology, diagnosis, and clinical management of COVID-19 have contributed to the control and prevention of this disease, but re-positivity of SARS-CoV-2 in recovered COVID-19 patients has brought a new challenge for this worldwide anti-viral battle. Reverse transcription polymerase chain reaction (RT-PCR) tests of the SARS-CoV-2 pathogen is widely used in clinical diagnosis, but a positive RT-PCR result may be multifactorial, including false positive, SARS-CoV-2 RNA fragment shedding, reinfection of SARS-CoV-2, or re-activation of COVID-19. Re-infection of SARS-CoV-2 or re-activation of COVID-19 is an indicator of live viral carriers and isolation/treatment is needed, but SARS-CoV-2 RNA fragment shedding is not. SARS-CoV-2 RNA is recently reported to integrate into the host genome, but the far-reaching outcome is currently unclear. Therefore, it is critical for appropriate manipulation and prevention of COVID-19 to distinguish these causal factors of SARS-CoV-2 re-positivity. In this review article, we updated the current knowledge of SARS-CoV-2 re-positivity in discharged COVID-19 patients with a focus on re-infection and re-activation. We proposed a hypothetical flowchart for handling of the SARS-CoV-2 re-positive cases.","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2021-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39057818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1